抗CD1a嵌合抗原受体T细胞以选择性靶向T细胞急性淋巴细胞白血病。 - Suppr

Suppr

超能文献

Anti-CD1a CAR T cells to selectively target T-ALL.

作者信息

Maciocia Paul M, Pule Martin A

机构信息

University College London.

Autolus Ltd.

出版信息

Blood. 2019 May 23;133(21):2246-2247. doi: 10.1182/blood-2019-03-900910.

DOI:10.1182/blood-2019-03-900910

PMID:31122936

Abstract

摘要

相似文献

Anti-CD1a CAR T cells to selectively target T-ALL.

Blood. 2019 May 23;133(21):2246-2247. doi: 10.1182/blood-2019-03-900910.

Immunophenotypic analysis of T-acute lymphoblastic leukemia. A CD5-based ETP-ALL perspective of non-ETP T-ALL.

Eur J Haematol. 2014 Mar;92(3):211-8. doi: 10.1111/ejh.12238. Epub 2014 Jan 10.

Anti-CD7 CAR T cells for T-ALL: impressive early-stage efficacy.

Nat Rev Clin Oncol. 2021 Nov;18(11):677-678. doi: 10.1038/s41571-021-00556-3.

2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.

J Hematol Oncol. 2019 May 16;12(1):49. doi: 10.1186/s13045-019-0732-7.

Adult T-cell leukemia/lymphoma with an unusual CD1a positive phenotype.

Cytometry B Clin Cytom. 2014 Jul;86(4):292-6. doi: 10.1002/cyto.b.21130. Epub 2013 Sep 30.

CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.

Blood. 2017 Jul 20;130(3):285-296. doi: 10.1182/blood-2017-01-761320. Epub 2017 May 24.

[Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Dec;22(6):1753-6. doi: 10.7534/j.issn.1009-2137.2014.06.047.

Distinct immunophenotype of early T-cell progenitors in T lymphoblastic leukemia/lymphoma may predict FMS-like tyrosine kinase 3 mutations.

Ann Diagn Pathol. 2012 Jan;16(1):16-20. doi: 10.1016/j.anndiagpath.2011.07.005. Epub 2011 Nov 3.

Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies.

Best Pract Res Clin Haematol. 2019 Dec;32(4):101097. doi: 10.1016/j.beha.2019.101097. Epub 2019 Oct 18.

"Dar"-ing to target CD38 in T-ALL.

Blood. 2018 Mar 1;131(9):948-949. doi: 10.1182/blood-2018-01-826446.

引用本文的文献

CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?

Blood Adv. 2025 Feb 25;9(4):913-923. doi: 10.1182/bloodadvances.2023012263.

Gene Targets of CAR-T Cell Therapy for Glioblastoma.

Cancers (Basel). 2023 Apr 18;15(8):2351. doi: 10.3390/cancers15082351.

CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities.

Vaccines (Basel). 2023 Jan 12;11(1):165. doi: 10.3390/vaccines11010165.

MYC in T-cell acute lymphoblastic leukemia: functional implications and targeted strategies.

Blood Sci. 2021 Jun 7;3(3):65-70. doi: 10.1097/BS9.0000000000000073. eCollection 2021 Jul.

Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of "On-Target, Off-Tumor Toxicity".

Front Immunol. 2021 Dec 16;12:799206. doi: 10.3389/fimmu.2021.799206. eCollection 2021.

Updates in the Treatment of Peripheral T-Cell Lymphomas.

J Exp Pharmacol. 2021 Jun 22;13:577-591. doi: 10.2147/JEP.S262344. eCollection 2021.

CD4-Targeted T Cells Rapidly Induce Remissions in Mice with T Cell Lymphoma.

Biomed Res Int. 2021 Mar 27;2021:6614784. doi: 10.1155/2021/6614784. eCollection 2021.

Early T-cell precursor acute lymphoblastic leukemia and other subtypes: a retrospective case report from a single pediatric center in China.

J Cancer Res Clin Oncol. 2021 Sep;147(9):2775-2788. doi: 10.1007/s00432-021-03551-4. Epub 2021 Mar 2.

Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19 Tumors.

J Clin Oncol. 2021 Feb 10;39(5):499-513. doi: 10.1200/JCO.20.01738. Epub 2021 Jan 12.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Anti-CD1a CAR T cells to selectively target T-ALL.

Blood. 2019 May 23;133(21):2246-2247. doi: 10.1182/blood-2019-03-900910.

Immunophenotypic analysis of T-acute lymphoblastic leukemia. A CD5-based ETP-ALL perspective of non-ETP T-ALL.

Eur J Haematol. 2014 Mar;92(3):211-8. doi: 10.1111/ejh.12238. Epub 2014 Jan 10.

Anti-CD7 CAR T cells for T-ALL: impressive early-stage efficacy.

Nat Rev Clin Oncol. 2021 Nov;18(11):677-678. doi: 10.1038/s41571-021-00556-3.

2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.

J Hematol Oncol. 2019 May 16;12(1):49. doi: 10.1186/s13045-019-0732-7.

Adult T-cell leukemia/lymphoma with an unusual CD1a positive phenotype.

Cytometry B Clin Cytom. 2014 Jul;86(4):292-6. doi: 10.1002/cyto.b.21130. Epub 2013 Sep 30.

CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.

Blood. 2017 Jul 20;130(3):285-296. doi: 10.1182/blood-2017-01-761320. Epub 2017 May 24.

[Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Dec;22(6):1753-6. doi: 10.7534/j.issn.1009-2137.2014.06.047.

Distinct immunophenotype of early T-cell progenitors in T lymphoblastic leukemia/lymphoma may predict FMS-like tyrosine kinase 3 mutations.

Ann Diagn Pathol. 2012 Jan;16(1):16-20. doi: 10.1016/j.anndiagpath.2011.07.005. Epub 2011 Nov 3.

Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies.

Best Pract Res Clin Haematol. 2019 Dec;32(4):101097. doi: 10.1016/j.beha.2019.101097. Epub 2019 Oct 18.

"Dar"-ing to target CD38 in T-ALL.

Blood. 2018 Mar 1;131(9):948-949. doi: 10.1182/blood-2018-01-826446.

引用本文的文献

CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?

Blood Adv. 2025 Feb 25;9(4):913-923. doi: 10.1182/bloodadvances.2023012263.

Gene Targets of CAR-T Cell Therapy for Glioblastoma.

Cancers (Basel). 2023 Apr 18;15(8):2351. doi: 10.3390/cancers15082351.

CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities.

Vaccines (Basel). 2023 Jan 12;11(1):165. doi: 10.3390/vaccines11010165.

MYC in T-cell acute lymphoblastic leukemia: functional implications and targeted strategies.

Blood Sci. 2021 Jun 7;3(3):65-70. doi: 10.1097/BS9.0000000000000073. eCollection 2021 Jul.

Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of "On-Target, Off-Tumor Toxicity".

Front Immunol. 2021 Dec 16;12:799206. doi: 10.3389/fimmu.2021.799206. eCollection 2021.

Updates in the Treatment of Peripheral T-Cell Lymphomas.

J Exp Pharmacol. 2021 Jun 22;13:577-591. doi: 10.2147/JEP.S262344. eCollection 2021.

CD4-Targeted T Cells Rapidly Induce Remissions in Mice with T Cell Lymphoma.

Biomed Res Int. 2021 Mar 27;2021:6614784. doi: 10.1155/2021/6614784. eCollection 2021.

Early T-cell precursor acute lymphoblastic leukemia and other subtypes: a retrospective case report from a single pediatric center in China.

J Cancer Res Clin Oncol. 2021 Sep;147(9):2775-2788. doi: 10.1007/s00432-021-03551-4. Epub 2021 Mar 2.

Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19 Tumors.

J Clin Oncol. 2021 Feb 10;39(5):499-513. doi: 10.1200/JCO.20.01738. Epub 2021 Jan 12.